This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Infirst HEALTHCARE To Commercialise Novel Consumer Healthcare Drugs

Founded in 2004, SEEK (previously known as PepTcell) is privately-owned and funded, with headquarters in London, UK. Using a pioneering scientific and commercially-driven approach, SEEK aims to create breakthrough medicines which address major diseases in order to radically improve human health. SEEK's strategy is to take promising molecules through the challenging stages of discovery to late-stage human proof-of-principle and then to seek partners to take the molecules through the final stages of development and ultimately commercialisation. Additional information about SEEK is available on the Company's website located at

About Invesco Perpetual

Invesco Perpetual is the trading name of Invesco Asset Management Limited and one of the largest independent investment managers in the UK. Their investment approach is rooted in the view that there are no short cuts to long-term investment success. Their fund managers have a wealth of expertise and are focused on achieving the objectives of the funds they manage. More information can be found on their web site at

About Cough

More common than heartburn and severe headaches, cough imposes a great burden on the sufferer, their families, and society.  Afflicting over 800 million worldwide, with an estimated 12% of the general population (7.5 million in the UK), experiencing the symptom on a regular basis. Most current cough remedies have old, grandfathered licenses and many are of narcotic/ opioid nature.

For more information please contact: Manfred Scheske, CEO, infirst HEALTHCARE :  Tel +44(0)20-7153-6570 M:Communications Mary Clark / Amber Bielecka / Hollie Vile - Tel +44(0)20-7920-2330 Peel Hunt LLP (Financial Adviser to infirst HEALTHCARE)   James Steel / Vijay Barathan:  Tel +44(0)20-7418-8900


Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs